Announcements

November 9, 2010: Snowdon, Inc., today announced that it has been awarded a new three-year contract from the Department of Defense (DoD) Program, Transformational Medical Technologies (TMT) for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens. Snowdon may receive up to $8.2 million in support of development efforts under this new Defense Threat Reduction Agency (DTRA) contract.

Snowdon is partnering with two centers of excellence at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS). The Center for Emerging Pathogens in the Department of Medicine, under the direction of Dr. Nancy Connell, will test Snowdon's drug candidates on specific biowarfare pathogens. The Center maintains high-level biosafety containment facilities for this purpose. Snowdon will also be assisted by the newly opened Regional Biocontainment Laboratory of UMDNJ under the direction of Dr. David Perlin, Director of the Public Health Research Institute (PHRI).

Snowdon has recently expanded its research and development space and facilities in the Princeton Research Center (Monmouth Junction, NJ) and has hired additional scientific staff and technical personnel. This DTRA contract will complement Snowdon's ongoing activities in the development of novel treatments for pain, nervous system disorders, and other infectious diseases. [read full press release at BusinessWire.com]

September 1, 2009: Snowdon was awarded a grant for $628,000 over two years by the U.S. National Institutes of Health (NIH) to develop novel therapies for toxoplasmosis, a serious parasitic disease that affects immuno-compromised individuals such as HIV infected patients and organ transplant recipients. The Company is collaborating on this project with Rima McLeod, M.D., a distinguished clinician-scientist at the University of Chicago Medical Center.

May 29, 2009: Snowdon was awarded a contract with the U.S. Food & Drug Administration (FDA) to develop computational tools for rapid detection of contaminants in active pharmaceutical ingredients.

May 1, 2008: Snowdon was awarded a $114,000 Phase I Small Business Innovation Research Award from the National Institutes of Health (NIH) - National Cancer Institute to support development of the company's novel lead compounds for colorectal cancer.

August 15, 2008: Snowdon was awarded a two-year $150,000 Technology Fellowship grant by the New Jersey Commission on Science & Technology (NJCST) to support Dr. Oyenike Olabisi for her research on novel anti-cancer treatments. Dr. Olabisi earned the Ph.D. degree in 2008 at the University of Medicine & Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS).

October 11, 2007: Snowdon was awarded a $130,000 Phase I Small Business Innovation Research Award from the National Institutes of Health (NIH) - National Institute of Neurological Disorders and Stroke (NINDS) to support development of the company's novel technology aimed at the prevention and treatment of protein misfolding diseases such as Alzheimer's disease and Parkinson's disease.

July 9, 2007: Snowdon’s success in attracting funding to development its potential drug candidates was featured in an article authored by Thomas Gaudio in NJBIZ magazine.

June 23, 2007: Snowdonwas awarded a two-year $500,000 Edison Innovation Award grant from the New Jersey Commission on Science & Technology (NJCST) to develop its lead compounds for the treatment of toxoplasmosis and related serious parasitic infections.

March 22, 2007: Snowdon secured $500,000 in venture capital funding from the Foundation Venture Capital Group LLC (FVCG). It is the venture firm's first investment.

home | therapeutic areas | our technology | about us | news | employment | contact us